达格列净在2型糖尿病一级预防人群中的心血管、肾脏及代谢结局:DECLARE-TIMI 58分析
DECLARE-TIMI 58研究纳入17,160例2型糖尿病患者,其中59.4%为多重心血管危险因素(MRF)人群,随机接受达格列净或安慰剂,中位随访4.2年。在MRF人群中,达格列净降低心血管死亡或心衰住院风险(HR 0.84,95%CI 0.67-1.04)及肾脏特异性结局风险(HR 0.51,95%CI 0.37-0.69),与ASCVD人群无差异。心衰住院风险降低(HR 0.64,95%CI 0.46-0.88)。
要点
- 达格列净降低MRF人群心衰住院风险(HR 0.64,95%CI 0.46-0.88)。
- 达格列净降低MRF人群肾脏特异性结局风险(HR 0.51,95%CI 0.37-0.69)。
- MRF人群的心血管和肾脏获益与ASCVD人群一致。
核心结论
- 在2型糖尿病合并多重心血管危险因素的患者中,达格列净降低心衰住院和不良肾脏结局风险,且不受基线特征影响。
研究设计与样本
- DECLARE-TIMI 58研究的事后分析,纳入17,160例2型糖尿病患者,其中多重心血管危险因素(MRF)患者占59.4%,已确诊动脉粥样硬化性心血管疾病(ASCVD)患者占40.6%,随机接受达格列净或安慰剂,中位随访4.2年。
主要发现
- 在MRF人群中,达格列净降低心血管死亡或心衰住院风险(HR 0.84,95%CI 0.67-1.04),与ASCVD人群无差异(P交互=0.99)。
- 在MRF人群中,达格列净降低肾脏特异性结局风险(HR 0.51,95%CI 0.37-0.69),与ASCVD人群无差异(P交互=0.72)。
- 达格列净对心血管死亡或心衰住院的效应完全由心衰住院减少驱动(HR 0.64,95%CI 0.46-0.88)。
- 在MRF人群中,达格列净对心衰住院和肾脏特异性结局的获益在临床相关亚组中方向一致。
- 48个月时,达格列净组HbA1c、体重、收缩压和尿白蛋白肌酐比值低于安慰剂组,估算肾小球滤过率高于安慰剂组(P<0.001)。
临床怎么用
- 对于2型糖尿病合并多重心血管危险因素的患者,可考虑使用达格列净以降低心衰住院和肾脏不良结局风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: International guidelines propose prescribing sodium-glucose cotransporter 2 (SGLT2) inhibitors to patients with type 2 diabetes (T2D) as secondary prevention in patients with established atherosclerotic cardiovascular disease (ASCVD) or for primary prevention of cardiovascular events in high-risk patients with multiple risk factors (MRF) for ASCVD. The current analyses expand on the cardiovascular renal and metabolic effects of SGLT2 inhibitors in MRF patients. RESEARCH DESIGN AND METHODS: In DECLARE-TIMI 58, 17,160 patients with T2D and MRF (59.4%) or established ASCVD (40.6%) were randomized to dapagliflozin versus placebo; patients were followed for a median of 4.2 years. The cardiovascular and renal outcomes in the MRF cohort were studied across clinically relevant subgroups for treatment effect and subgroup-based treatment interaction. RESULTS: Among patients with MRF, the reduction with dapagliflozin in risk of cardiovascular death or hospitalization for heart failure (CVD/HHF) (hazard ratio [HR] 0.84, 95% CI 0.67-1.04) and the renal-specific outcome (HR 0.51, 95% CI 0.37-0.69) did not differ from that for patients with ASCVD (P interaction 0.99 and 0.72, respectively). The effect on CVD/HHF was entirely driven by a reduction in HHF (HR 0.64, 95% CI 0.46-0.88). The benefits of dapagliflozin on HHF and on the renal-specific outcome, among the subset with MRF, were directionally consistent across clinically relevant subgroups. At 48 months, HbA1c, weight, systolic blood pressure, and urinary albumin-to-creatinine ratio were lower with dapagliflozin versus placebo and estimated glomerular filtration rate was higher (P < 0.001). CONCLUSIONS: In patients with T2D and MRF, dapagliflozin reduced the risk of HHF and adverse renal outcomes regardless of baseline characteristics. These analyses support the benefit of dapagliflozin for important outcomes in a broad primary prevention population.
引用
- Cahn A, Raz I, Leiter LA, et al. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care. 2021. PMID: 33653824. doi:10.2337/dc20-2492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。